Page last updated: 2024-10-16

carnitine and Thymus Neoplasms

carnitine has been researched along with Thymus Neoplasms in 1 studies

Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.

Research Excerpts

ExcerptRelevanceReference
"The mechanism(s) of immune checkpoint inhibitor (ICI)-induced myasthenia gravis (MG), an immune-related adverse event (irAE) that is fatal and limits subsequent ICI use, remain unexplored."1.72Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. ( Chen, L; Gao, W; Gong, Q; Guo, R; Jin, S; Li, J; Liu, X; Shao, YW; Shen, L; Sun, C; Wang, Q; Wang, W; Wang, Z; Wu, L; Xu, J; Yin, JC; Zhang, W, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gao, W3
Wu, L3
Jin, S3
Li, J3
Liu, X3
Xu, J3
Zhang, W3
Gong, Q3
Sun, C3
Wang, W3
Wang, Z3
Shao, YW3
Yin, JC3
Shen, L3
Chen, L3
Wang, Q3
Guo, R3

Other Studies

1 other study available for carnitine and Thymus Neoplasms

ArticleYear
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member

2022
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member

2022
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member

2022
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member

2022